Jianying Zhou

发表论文 259 篇 · 总被引 14078 次 · h-index 51

代表论文

• AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations (2022 · Journal of Clinical Oncology · 被引 247)
• Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. (2023 · Journal of Clinical Oncology · 被引 85)
• D-1553 (garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients with Non-Small Cell Lung Cancer: Phase I Study Results. (2023 · Journal of Thoracic Oncology · 被引 75)
• Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial. (2023 · Journal of Thoracic Oncology · 被引 66)
• Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis (2023 · Clinical Cancer Research · 被引 36)
• Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial (2023 · Signal Transduction and Targeted Therapy · 被引 34)